In a Russian multicenter randomized study in 189 patients with chronic cerebral ischemia, intramuscular cortexin reduced neurological symptoms, asthenia and sleep disturbance in a dose-dependent way compared with basic treatment alone.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
In a Russian multicenter randomized study in 189 patients with chronic cerebral ischemia, intramuscular cortexin reduced neurological symptoms, asthenia and sleep disturbance in a dose-dependent way compared with basic treatment alone. · pmid:30335070
Classification
Cortexin is a lyophilised extract of animal cerebral cortex containing neuropeptides, amino acids and trace elements; it is not a single defined compound. · pmid:26356623
Mechanism
In rat models of acute and chronic brain ischemia, cortexin improved recovery of neurological function and reduced tissue damage; labelled cortexin crossed the blood-brain barrier in mice at 6-8% of blood levels. · pmid:34260655
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Emerging33%
Preclinical only67%
Proportion of the 3 claims about Cortexin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
3 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Cortexin yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
nothing resolved on this rung
Observational evidence· resolved human data at the emerging tier: thin, or contested
[Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study)]. · pmid 30335070 · 2018
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
[Cortexin. Molecular mechanisms and targets of neuroprotective activity]. · pmid 26356623 · 2015
Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. · pmid 34260655 · 2021
3 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.